Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Molecular response to PARP1 inhibition in ovarian cancer cells as determined by mass spectrometry based proteomics

[thumbnail of Original Article]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
2MB
[thumbnail of Supplementary Material] Other (Supplementary Material)
1MB

Item Type:Article
Title:Molecular response to PARP1 inhibition in ovarian cancer cells as determined by mass spectrometry based proteomics
Creators Name:Franz, A., Coscia, F., Shen, C., Charaoui, L., Mann, M. and Sander, C.
Abstract:BACKGROUND: Poly (ADP)-ribose polymerase (PARP) inhibitors have entered routine clinical practice for the treatment of high-grade serous ovarian cancer (HGSOC), yet the molecular mechanisms underlying treatment response to PARP1 inhibition (PARP1i) are not fully understood. METHODS: Here, we used unbiased mass spectrometry based proteomics with data-driven protein network analysis to systematically characterize how HGSOC cells respond to PARP1i treatment. RESULTS: We found that PARP1i leads to pronounced proteomic changes in a diverse set of cellular processes in HGSOC cancer cells, consistent with transcript changes in an independent perturbation dataset. We interpret decreases in the levels of the pro-proliferative transcription factors SP1 and ß-catenin and in growth factor signaling as reflecting the anti-proliferative effect of PARP1i; and the strong activation of pro-survival processes NF-?B signaling and lipid metabolism as PARPi-induced adaptive resistance mechanisms. Based on these observations, we nominate several protein targets for therapeutic inhibition in combination with PARP1i. When tested experimentally, the combination of PARPi with an inhibitor of fatty acid synthase (TVB-2640) has a 3-fold synergistic effect and is therefore of particular pre-clinical interest. CONCLUSION: Our study improves the current understanding of PARP1 function, highlights the potential that the anti-tumor efficacy of PARP1i may not only rely on DNA damage repair mechanisms and informs on the rational design of PARP1i combination therapies in ovarian cancer.
Keywords:PARP Inhibitors, High-Grade Serous Ovarian Cancer, Mass Spectrometry Based Proteomics, Molecular Response Profiling, Pathway Analysis, Data-Driven Protein Module Discovery, Molecular Signaling Pathways, PARP Inhibitor Resistance, Combination Therapy
Source:Journal of Ovarian Research
ISSN:1757-2215
Publisher:BioMed Central
Volume:14
Number:1
Page Range:140
Date:22 October 2021
Official Publication:https://doi.org/10.1186/s13048-021-00886-x
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library